> In business terms it's a win, but not very much for the public. It's a win for the public, because the public cost in medical bills, insurance claims, medica

> In business terms it's a win, but not very much for the public. It's a win for the public, because the public cost in medical bills, insurance claims, medicare, suffering, and death from vaccine hesitancy far outweighs the cost of highly infrequent payouts.